Abstract The placenta contains a large variety of metabolizing enzymes, among them UDP-glucuronosyltransferase (UGT). Several UGT2B isozymes have so far been detected in human placenta, but little is known on placental expression of UGT1A isozymes. The antiepileptic drug lamotrigine (LTG) is a UGT1A4-substrate, and its serum concentration falls by over 50% during pregnancy, leading to impaired seizure control. The placenta may be involved in this. Microsomes from term placentas of 4 LTG-users and 10 healthy control subjects were prepared. Western blot analysis detected UGT1A proteins in all placentas. The presence of UGT1A4 in placenta from LTG users was confirmed with UGT1A4 commercial standard and a specific UGT1A4 primary antibody. Since LTG is primarily metabolized by UGT1A4 and this isozyme is shown to be present in placenta at term, it may be hypothesized that the placenta is involved in the fall of LTG serum concentrations during pregnancy.
Introduction
UDP-glucuronosyltransferases (UGTs) are a mammalian superfamily of phase II metabolizing enzymes, of which UGT1A and UGT2B are the most important subfamilies. To date, 25 UGT1A and UGT2B isozymes have been identified in humans (Mackenzie et al. 2005) . UGTs catalyze the binding of glucuronic acid to endo-and exogenous compounds, e.g., hormones or drugs. This is an important process that increases their solubility in water and aids in their urinary excretion. UGTs have been found in a variety of organs and tissues, including liver, lungs, intestinal mucosa, brain, uterus and placenta, in both animals and humans (Mackenzie et al. 2005; Myllynen et al. 2005 Myllynen et al. , 2007 Nakamura et al. 2008; Syme et al. 2004 ).
UGT activity is regulated by various pre-and posttranslational mechanisms, e.g., hormones, liver-enriched transcription factors, ligand-activated transcription factors, and the aryl hydrocarbon receptor (Bock 2010; Ishii et al. 2010) . These findings relate mostly to experiments with hepatic UGT. Very little is known on the extent and intrinsic regulation of human placental UGT activity. External factors, e.g., enzyme-inducing drugs, ethinyl estradiol or cigarette smoke may increase UGT activity. Some UGT1A4-substrates, e.g., the antiepileptic drug lamotrigine (LTG), may even induce their own metabolism to a certain degree (Hussein and Posner 1997; May et al. 1996; Ohman et al. 2008; Reimers et al. 2005; Villard et al. 1998) .
LTG serum concentrations fall by over 50% during pregnancy, most presumably due to increased glucuronidation (de Haan et al. 2004; Ohman et al. 2008 Ohman et al. , 2000 Pennell et al. 2004; Petrenaite et al. 2005) . This may lead to loss of seizure control and the necessity to increase the LTG dose (Petrenaite et al. 2005) . It is unlikely that pregnancy-induced hemodilution plays a major role in this phenomenon as hematocrit usually decreases by only 10-15% (Klajnbard et al. 2010) . Moreover, it has been shown that increased glucuronidation of LTG is the most probable mechanism (Ohman et al. 2008) . It is reasonable to assume that most of this glucuronidation takes place in the liver. However, UGT has been found in many other tissues also, including the placenta. The placenta is a major detoxifying organ, protecting the fetus from potentially harmful compounds by means of various enzymes and transporters (Myllynen et al. 2005 (Myllynen et al. , 2007 Syme et al. 2004) . In contrast to the placental expression of cytochrome P450 enzymes, data on placental UGT expression is scarce. So far, few different isozymes of the UGT2B-family have been detected in placental tissue. UGT1A protein expression was found in first trimester human placenta, but not in placenta at term (Collier et al. 2002a, b) . Unfortunately, these studies did not distinguish between the different UGT1A isozymes. A more recent study found DNA-transcripts of UGT1A6, but no other UGT1A isozyme, in placental tissue (Zhang et al. 2007 ).
Since it is unknown where in the body the increased glucuronidation of LTG takes place, and which role the placenta plays in this context, we wished to investigate whether UGT1A4 is expressed in human placenta.
Methods

Placenta specimens and preparation of microsomes
Placentas from 10 healthy, non-smoking, normal-term pregnant women (controls; samples 1-10) and four nonsmoking, normal-term pregnant women using LTG without enzyme-inducing co-medication (LTG-users; samples 11-14) were taken immediately after cesarean section or vaginal delivery and microsomes of the villous part were prepared within 30 min. Microsomes were prepared by calcium precipitation according to Kamath and Rubin (1972) . Briefly, villous tissue from the placenta was homogenized in 0.25 M icecold sucrose and the homogenate was centrifuged at 12,000g for 20 min to obtain a postmitochondrial supernatant (PMS). The PMS was subjected to microsomal aggregation by addition of Ca 2? and then centrifuged again at 27,000g for 15 min. The microsomal pellets obtained were suspended in 0.1 M Tris buffer (pH 7.4), added glycerol (final glycerol concentration was 15%) and stored at -80°C until use. Preparation of microsomes was performed at 4°C. The protein concentrations were determined using the Bradford protein assay (Bio-Rad Laboratories), with bovine serum albumin as the protein standard (Bradford 1976) .
All study subjects gave their written informed consent. The study was approved by the regional ethics committee.
Western blotting
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to the method of Laemmli (1970) , with minor modifications. Western blot analysis was performed basically according to Towbin et al. (1979) . Placental microsomal proteins were denaturated by boiling for 4 min in sample treatment buffer (0.125 M Tris-HCl, pH 6.8, 20% glycerol, 4% sodium dodecyl sulfate, 0.004% bromophenol blue, and 10% 2-mercaptoethanol). Placental microsomal proteins were loaded (30 lg per lane) and separated using 4-20% linear gradient gel in Tris-HCl (Bio-Rad Laboratories) for approximately 50 min at 200 V. Human UGT1A4 supersomes (BD Gentest) were treated in sample treatment buffer analogous to the placental microsomes and then loaded as standard. In addition, human UGT1A1 microsomes (BD Gentest) were loaded as standard. The resolved proteins were transferred electrophoretically to a 0.45-lm nitrocellulose membrane (BioRad Laboratories) at 100 V for 1 h. The nitrocellulose sheets were blocked overnight by treatment with 5% skim milk in Tris-buffered saline (TBS) containing 0.1% Tween20. The membranes were rinsed and treated for 1 h with a 1:1,000 dilution of WB-UGT1A primary antiserum (BD Gentest) or a 1:500 dilution of a specific UGT1A4 primary antiserum (Santa Cruz Biotechnology). The membranes were rinsed four times for 10 min and incubated for 1 h with a 1:1,000 dilution of horse radish peroxidase (HRP) conjugated goat anti-rabbit IgG (BD Gentest) or a 1:5,000 dilution of HRP conjugated donkey anti-goat IgG (Santa Cruz Biotechnology), respectively.
Membranes were washed four times with TBS and visualized using Western Lightning Chemiluminescence reagents according to the manufacturer's instructions (BD Gentest and Santa Cruz Biotechnology) followed by light detection on luminescence detection film (Amersham Bioscience).
Results and discussion
UGT1A proteins were detected, using WB-UGT1A primary antibody, in all four placental samples from women using LTG (Fig. 1a) . Two bands were detected in every sample, and one of them co-migrated with the UGT1A4 standard. Western blot analyses with UGT1A4 primary antibody also illustrated the presence of bands, further indicating the presence of the UGT1A4 isozyme (Fig. 1b) . The other band detected by WB-UGT1A (Fig. 1a) corresponded to neither the UGT1A4 nor the UGT1A1 standard, which indicates the presence of another isoform of UGT1A in the placenta samples. The WB-UGT1A primary antibody used in this study detects several isoforms of human UGT1A (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 1A10 (mobility range 52-58 kDa)). In a previous study, DNAtranscripts of UGT1A6, but not UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A7, UGT1A8, UGT1A9, and UGT1A10, have been found in human placenta (Zhang et al. 2007 ). Thus, the unidentified band may be caused by UGT1A6. The fact that this latter study did not find evidence for placental expression of UGT1A4 may be due to considerable methodological differences (DNA-transcripts vs. UGT1A4 protein itself) and the use of a different kind of placental tissue preparation.
UGT1A proteins were also detected in placental samples from the 10 control women not using LTG. A representative immunoblot of microsomes from control women (showing samples 1-7) and UGT1A4 standard is shown in Fig. 2 . Although equal amounts of total placental protein and UGT1A4 standard were used in the different immunoblots, weaker bands of UGT1A were detected in the placentas of the control group (Fig. 2) , compared to the LTG-user group (Fig. 1) . However, our experiments, which were designed to detect UGT1A and UGT1A4 qualitatively, were not suited for quantitative measurements. Moreover, only four placentas were available from LTG-users. Thus, the observed differences in band intensity do not prove real quantitative differences in UGT1A4 expression. It has, though, previously been found that LTG induces its own metabolism (Hussein and Posner 1997) . Therefore, it may be hypothesized that LTG-users express higher levels of UGT1A4 than controls due to enzyme induction. Quantitative studies are needed to prove this theory.
UGT1A4 mRNA has previously been found in human liver, stomach, small intestine, colon, kidney, bladder, trachea and ovary, but not in brain, lung, adrenal gland, breast, uterus and testis (Kaivosaari et al. 2007 , Nakamura et al. 2008 ). To our knowledge, our study is the first one to demonstrate UGT1A4 protein in human term placenta. This finding suggests that placental UGT1A4 activity may contribute to the significant fall of LTG serum concentrations during pregnancy. Further studies, e.g., quantitative Western blots and metabolizing experiments with placental tissue or whole perfused placentas are necessary to confirm our findings and to evaluate this hypothesis.
